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Background: The twice daily administration of an inhaled corticosteroid (ICS) and long-
acting beta2-agonist (LABA) has been shown to be effective in achieving asthma control.
The once daily administration of an ICS/LABA may be a treatment option for some
patients.
Objective: To assess the effectiveness of ﬂuticasone propionate (FP)/salmeterol via a
single inhaler (FSC) administered once daily compared with FP once daily, FSC twice daily,
or placebo.
Methods: A 12-week, randomized, double-blind multicenter study conducted in 844
patientsX12 years of age who were symptomatic while using a short-acting beta2-agonist
alone. Blinded treatments included: FSC 250/50mcg once daily in the evening (FSC 250/50
QD), FP 250mcg once daily in the evening (FP 250 QD), FSC 100/50mcg twice daily (FSC
100/50mcg BID), or placebo. All treatments were delivered via the Diskuss device.
Results: All treatments demonstrated greater improvements in efﬁcacy measures
compared with placebo. Overall, the greatest improvements were observed in the
patients receiving FSC, either once or twice daily, compared with the FP 250 QD group. The
two FSC treatments were similar except that QD dosing did not maintain improvements in
lung function for 24 h compared with twice daily dosing. All treatments were wellElsevier Ltd. All rights reserved.
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E.M. Kerwin et al.496tolerated. No suppression of HPA axis, as assessed by 24-h urinary cortisol excretion, was
observed in any of the active treatment groups.
Conclusion: In patients symptomatic on a short-acting beta2-agonist alone, FSC 100/50mcg
BID was shown to provide better efﬁcacy than a higher strength (FSC 250/50mcg)
administered once daily. However, a once daily regimen was effective and may be a
valuable treatment option for some patients.
Registered at http://ctr.gsk.co.uk/welcome.asp (SAS30022)
& 2007 Elsevier Ltd. All rights reserved.Introduction
Current guidelines recommend the use of anti-inﬂammatory
medications, including inhaled corticosteroids (ICS), and
long-acting beta2-agonists (LABA) for the treatment of
persistent asthma. It is also recommended that the least
amount of medication be used to maintain asthma control.1,2
Fluticasone propionate (FP), an ICS, is available in
multiple strengths to aid the individualization of treatment
and is approved for twice daily administration. However,
data suggest that FP may be suitable for once daily
administration in some patients. For example, clinical
studies have shown FP to be effective when compared with
placebo when given once-a-day.3–6 Nonetheless, when the
total daily dose of FP is given twice daily, it is generally more
effective than once daily dosing.7
Salmeterol is also approved for use as a twice daily
regimen. Clinical studies have shown that the effect of
salmeterol on bronchodilation, protection against bronchial
hyperresponsiveness, and other clinical measures exceed
12 h, suggesting that in some patients, salmeterol may exert
therapeutic efﬁcacy when given once daily.8–12
Given the results obtained in some studies with once daily
dosing with FP and other ICS,13–17 together with studies
demonstrating a duration of action of salmeterol exceeding
12 h, this study was conducted to determine the efﬁcacy and
safety of FP/salmeterol 250/50mcg administered once daily
in the evening (FSC 250/50 QD) compared with FP 250mcg
administered once daily in the evening (FP 250 QD), FSC
100/50mcg administered twice daily (FSC 100/50 BID), or
placebo (PLA) in symptomatic adolescent and adult patients
with asthma using short-acting beta2-agonists alone. All
treatments in this study were delivered via the Diskuss.Methods
Patients
Male and female patients were eligible for the study if they
were at least 12 years of age, had a medical history of
asthma (as deﬁned by the American Thoracic Society)18
requiring physician prescribed asthma therapy for at least
3 months duration, and were using short-acting beta2-
agonists alone for at least 1 month prior to screening. At
screening, patients were required to have a forced
expiratory volume in 1 s (FEV1) between 50% and 85%
predicted value before administration of a bronchodilator
and demonstrate a X12% increase in FEV1 within 30min
following two puffs (180mcg) of inhaled albuterol.Exclusion criteria included: history of life-threatening
asthma, smoking within the previous year or a history of
410 pack years, respiratory tract infection within 2 weeks
of screening, history of signiﬁcant concurrent disease, or the
use of prophylactic short-acting beta2-agonists of more than
two puffs/day or use on more than 5 days/week. All patients
(or parent/guardian if o18 years of age) provided written
informed consent prior to entry into the study. The protocol
was approved by the appropriate Institutional Review Board
or Ethics Committee for each participating site.Study design and interventions
This 12-week, randomized, double-blind, placebo-controlled,
parallel-group study (SAS30022) was conducted at 103 sites in
the United States and 18 sites in Canada. Eligible patients
entered a 2-week placebo run-in period to assess compliance
with therapy, obtain baseline data, conﬁrm asthma stability,
and evaluate eligibility for randomization to blinded treat-
ment. All patients were supplied with albuterol inhalation
aerosol for the relief of asthma symptoms as needed. Patients
who met the entry criteria for the run-in period were provided
two Diskus inhalers, each containing placebo to administer
twice daily (one Diskus to be administered in the morning and
the other in the evening, approximately 12h apart). The
morning and evening Diskus devices were differentiated by a
different color label. Compliance with blinded study treat-
ment was measured by the dose counter on the Diskus.
Patients were instructed on the use of a peak ﬂow
meter (MiniWrights, Clement Clark, Inc., London, United
Kingdom) and completing a daily diary record of morning
and evening peak ﬂow measurements, albuterol use, and
asthma symptoms. A nighttime asthma symptom score was
recorded in the morning (scale 0–4 [0 ¼ no symptoms;
4 ¼ symptoms so severe patient did not sleep at all]) and
every evening, a daytime asthma symptom score was
recorded (scale 0–5 [0 ¼ no symptoms; 5 ¼ symptoms so
severe that patient could not go to work/school or perform
normal daily activities]). To be eligible for randomization
patients had to have during the 7 days prior to the
randomization visit: an asthma symptom score (combined
daytime and nighttime) ofX2 or used albuterol onX4 days,
an evening PEF between 50% and 90% of predicted, and
demonstrate an FEV1 within 715% of the pre-bronchodila-
tion screening FEV1 at the randomization visit. Patients
entering the double-blind phase were randomly assigned to
receive one of the following four treatments for 12 weeks:
FSC 250/50mcg QD, FP 250mcg QD, FSC 100/50mcg BID, or
placebo BID. Patients assigned to once daily treatment had
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placebo in the morning.
Efﬁcacy measures
The primary efﬁcacy measure was change from baseline
over Weeks 1–12 in percent predicted evening PEF.
Secondary and other efﬁcacy measures included change
from baseline over Weeks 1–12 in evening and morning PEF,
change from baseline in the evening PEF 2 h following the
ﬁrst dose of study medication, and change from baseline at
endpoint in clinic FEV1, rescue albuterol use, and asthma
symptom scores. The morning and evening PEF measure-
ments (highest value of three attempts) were recorded by
the patient each day prior to taking the morning and evening
dose of study medication.
Baseline for the efﬁcacy measures obtained from diary data
was deﬁned as the average of the 7 days prior to randomiza-
tion. The 24-h asthma symptom score was calculated from the
addition of the daytime score and nighttime score where an
increase in score correlated to an increase in symptoms.
Endpoint for evening and morning PEF was the average over
Weeks 1–12. Endpoint for FEV1 was the last, on-treatment
FEV1, and for 24-h albuterol use and 24-h asthma symptom
scores endpoint was average of the last 7 consecutive days of
treatment values. In order to assess the relative onset of
effect following the ﬁrst dose of blinded study medication
lung function was measured 2h after the ﬁrst dose. Baseline
for the 2-h post-dose evening PEF measurement was the
evening PEF measured prior to taking the ﬁrst dose of blinded
medication and post-dose was the measurement taken 2h
later. Since this was patient-recorded data and not observed
in the clinic, data from patients who did not perform both
measurements or conduct the 2-h measure within715min of
the scheduled time point were excluded from this analysis.
Safety assessments
Safety was evaluated through adverse event (AE) monitor-
ing, 24-h urinary cortisol excretion, and percentage of
patients withdrawn due to worsening of asthma. AEs were
assessed at all clinic visits and a 24-h urine collection for
urinary cortisol excretion was collected at baseline and
after 12 weeks of treatment. A patient was required to be
withdrawn from the study for worsening of asthma if the
following occurred in the 7 days prior to a clinic visit: (1)42
days in which X12 puffs of albuterol were used or; (2) 43
days in which the morning or evening PEF fell below the
stability limit (20% drop from mean baseline morning or
evening PEF). A patient was withdrawn at anytime during
the study if an asthma exacerbation occurred (deﬁned as
need for treatment with medication other than rescue
albuterol or double-blind study medication).
Statistical analysis
The Intent-to-Treat (ITT) population, deﬁned as all patients
who were randomized and received at least one dose of
double-blind study medication, was the population used for
the analyses of all data (e.g., demographic, efﬁcacy and
safety) with the exception of urinary cortisol excretion. Theurinary cortisol population was deﬁned as the ITT population
excluding patients providing inadequate urine volumes or
collection times, or samples from patients who used prohibited
corticosteroid medication or were missing the baseline and/or
end of treatment assessment. This was the primary population
for analysis of 24-h urinary cortisol excretion.
The treatment comparison of primary interest was FSC
250/50 QD vs. FP 250 QD. Other treatment comparisons of
interest included FP 250 QD vs. placebo and FSC 250/50 QD
vs. FSC 100/50 BID. Using a two-sample, two-sided t-test,
with a 0.05 signiﬁcance level the standard deviation across
all treatment groups of 8.9%, 208 patients per treatment
group provided 95% power to detect a difference of 3.2% in
mean change from baseline over Weeks 1–12 in percent of
predicted evening PEF between any two treatment groups.
The 3.2% difference was estimated to be 15 L/min in PEF.
The efﬁcacy measures, with the exception of 24-h
albuterol use, were analyzed using analysis of covariance
(ANCOVA) adjusting for region (geographical grouping of
investigational sites), baseline value, age, and gender.
Twenty-four hour albuterol use was analyzed using non-
parametric ANCOVA (an extension of the aligned ranks
test).19 All statistical tests performed tested two-sided
hypotheses of no difference between treatment groups. The
endpoint analyses for measures over Weeks 1–12 included all
randomized subjects and was the average on-treatment
non-missing values during those weeks. Endpoint for FEV1
was the last on-treatment FEV1 measurement and for
albuterol use and asthma symptom scores was the average
of the last 7 days on-treatment values.
Multiple comparisons were controlled using the primary
treatment comparison of the primary efﬁcacy endpoint as a
gatekeeper, and performing tests of the secondary efﬁcacy
endpoints sequentially. To control for multiplicity across
other efﬁcacy endpoints, step-down rules whereby for a
given measure statistical testing may only be interpreted if
the test of the previous measure was considered inferen-
tially signiﬁcant were used for interpretation of results.
Results
A total of 1946 patients were screened for the study, of
whom 844 were randomly assigned to one of four treatments
(Figure 1). Randomization resulted in comparable treatment
groups at baseline with respect to demographics and
pulmonary function (Table 1). Approximately 3/4 of patients
were Caucasian and mean morning FEV1 per treatment
group was approximately 74% of predicted normal with a
mean FEV1 reversibility of 24–25%. For patients with a
baseline FEV1% predicted of o60% (12% of patients) the
mean reversibility was 35%; for those 60% to o80% of
predicted (58% of patients) the mean reversibility was 25%;
and for thoseX80% of predicted (30% of patients) the mean
reversibility was 21%. More patients randomized to placebo
withdrew from the study compared with the active treat-
ment groups (Figure 1). Compliance with double-blind study
medication was 94–97% across treatment groups.
Efﬁcacy
Efﬁcacy results for this study are presented in Tables 2
and 3. At baseline, the percent of predicted evening PEF
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Patients assessed for eligibility (n=1,946)
Patients excluded at screening or during 
run-in (n=1,102)
Reasons for exclusion*:
Not meeting entry criteria (n=1379)
Withdrawal of consent (n=41)
Prohibited medication use (n=7)
Adverse event (n=14)
Lost to follow-up (n=28)
Other (n=21)
FSC 250/50 
QD
(n=210)
Placebo
(n=212)
FP 250 
QD
(n=212)
Completed
(n=174)
Completed
(n=182)
Completed
(n=163)
Discontinued (n=36)
Worsening asthma   4
Adverse event          5 
Protocol violation    14
Other                      13
Discontinued (n=31)
Worsening asthma   4
Adverse event          6
Protocol violation    14
Other                        7
Discontinued (n=30)
Worsening asthma  6
Adverse event         1
Protocol violation   10
Other                     13
Discontinued (n=49)
Worsening asthma   17
Adverse event            3
Protocol violation      11
Other                        18
Randomized (n=844)
FSC 100/50 
BID
(n=210)
Completed
(n=179)
*A patient could have had more than one reason for withdrawal prior to randomization.  A total of 
1,490 reasons were recorded for the 1,102 patients who were excluded prior to randomization.
Figure 1 Enrollment, randomization, and follow-up of patients.
Table 1 Baseline demographics and pulmonary function.
FSC 250/50mcg QD
N ¼ 210
FP 250mcg QD
N ¼ 212
FSC 100/50mcg BID
N ¼ 210
PLA
N ¼ 212
Male/female (%) 40/60 47/53 50/50 48/52
Mean age, yr (range) 33.4 (12–73) 31.7 (12–85) 33.5 (12–71) 33.0 (12–73)
Race/ethnicity, n (%)
Caucasian 160 (76) 167 (79) 165 (79) 160 (75)
African-American 23 (11) 26 (12) 22 (10) 29 (14)
Asian 6 (3) 2 (o1) 4 (2) 4 (2)
Hispanic 16 (8) 16 (8) 17 (8) 16 (8)
Other 5 (2) 1 (o1) 2 (o1) 3 (1)
FEV1% (L), mean, (SD) 2.50 (0.63) 2.59 (0.68) 2.51 (0.66) 2.48 (0.58)
FEV1% predicted (SD) 74.4 (10.8) 74.5 (10.5) 72.8 (10.3) 73.2 (10.8)
FEV1% reversibility, mean (SD) 25.9 (14.6) 24.6 (11.8) 25.9 (13.3) 24.1 (11.4)
FSC, ﬂuticasone propionate/salmeterol; FP, ﬂuticasone propionate; PLA, placebo.
E.M. Kerwin et al.498ranged from 75.8% to 78.0% across treatment groups. Over
12 weeks of treatment FSC 250/50 QD demonstrated
statistically signiﬁcant (p ¼ 0.001) improvement compared
with FP 250 QD in percent predicted evening PEF corres-ponding to a 10.9 L/min difference between the two
treatments. Improvements in evening PEF for FSC 250/50
QD were seen at Week 1 and sustained throughout all weekly
time points without loss of effect (Figure 2). Signiﬁcant
ARTICLE IN PRESS
Table 2 Efﬁcacy measures: change from baseline.
FSC 250/50mcg QD
N ¼ 210
FP 250mcg QD
N ¼ 212
FSC 100/50mcg BID
N ¼ 210
PLA
N ¼ 212
% Predicted PM PEF, Weeks 1–12
Baseline mean (SE) 78.0 (0.72) 76.3 (0.75) 76.2 (0.79) 75.8 (0.76)
Adjusted mean change (SE) 8.3 (0.61) 5.5 (0.60) 10.1 (0.60) 3.2 (0.60)
PM PEF over Weeks 1–12 (L/min)
Baseline mean (SE) 363 (5.5) 367 (6.0) 367 (5.6) 358 (5.2)
Adjusted mean change (SE) 38.8 (2.9) 27.9 (2.8) 48.7 (2.8) 15.7 (2.8)
AM PEF over Weeks 1–12 (L/min)
Baseline mean (SE) 348 (5.5) 348 (5.7) 349 (5.6) 344 (5.0)
Adjusted mean change (SE) 51.7 (3.0) 33.6 (3.0) 57.1 (3.0) 12.6 (3.0)
AM FEV1 at endpoint (L)
Baseline mean (SE) 2.50 (0.04) 2.59 (0.05) 2.51 (0.05) 2.48 (0.04)
Adjusted mean change (SE) 0.49 (0.03) 0.36 (0.03) 0.48 (0.03) 0.18 (0.03)
24-h asthma symptom score at
endpoint
Baseline mean (SE) 2.7 (0.09) 2.9 (0.10) 2.6 (0.09) 2.7 (0.10)
Adjusted mean change (SE) 1.3 (0.10) 1.1 (0.10) 1.4 (0.10) 0.7 (0.10)
24-h albuterol use at endpoint
Baseline (SE) 3.3 (0.19) 3.4 (0.20) 2.9 (0.18) 3.2 (0.17)
Adjusted mean change (SE) 1.9 (0.18) 1.5 (0.19) 1.8 (0.17) 0.4 (0.15)
2-h post-dose PM PEF (L/min)
Baseline (SE) 366 (7.54) 373 (9.44) 371 (8.07) 368 (7.42)
Adjusted mean change (SE) 40.2 (3.88) 13.1 (4.11) 38.4 (3.53) 13.2 (3.91)
FSC, ﬂuticasone propionate/salmeterol; FP, ﬂuticasone propionate; PLA, placebo.
Use of ﬂuticasone propionate/salmeterol once daily 499(pp0.001) improvement was seen for FSC 250/50 QD
compared with FP 250 QD in the 2-h evening PEF measure-
ment after the ﬁrst dose of study medication (Figure 3). In
addition, patients receiving FSC 250/50 QD demonstrated
greater improvements in the 24-h asthma symptom scores
than those treated with FP 250 QD. These improvements
started at Week 1 and were sustained throughout the study
and were statistically signiﬁcant (pp0.050) at 6 of the 12
weekly time points. At baseline 24-h albuterol use ranged
from 2.9 to 3.4 puffs/day across groups. At endpoint a
statistically signiﬁcant (p ¼ 0.041) decrease in albuterol use
was seen for FSC 250/50 QD compared with FP 250 QD
(decrease of 1.85 vs. 1.45 puffs, respectively). The reduc-
tion in the need for rescue albuterol was seen across all
weekly time points over the 12 weeks of treatment.
The results observed in morning PEF were consistent with
those seen in evening PEF for the FSC 250/50 QD and FP 250
QD groups. The improvements in morning clinic FEV1 were
also statistically signiﬁcantly (p ¼ 0.003) greater in the FSC
250/50 QD compared with FP 250 QD group.
The three active treatments demonstrated greater
improvements in all measures of efﬁcacy compared with
placebo, with the exception of FP 250 QD vs. placebo for the
2-h post-dose evening PEF. However, the greatest improve-
ments were observed in patients treated with FSC,
administered as FSC 250/50 QD or FSC 100/50 BID compared
with those who received an equivalent daily dose of an ICSalone administered once daily (FP 250 QD). The administra-
tion of FSC 100/50 BID resulted in greater improvements
than FSC 250/50 QD in evening PEF and morning PEF. At
endpoint no difference was demonstrated in FEV1 between
FSC 250/50 QD and FSC 100/50 BID, and the improvements
seen in 24-h albuterol use and 24-h asthma symptom scores
were comparable for these two groups.
To assess the effect of acute dosing, PEF measures were
taken 2h after the ﬁrst dose of blinded treatment. A total of
95–117 patients in each treatment group were included in the
measure. Treatment with both FSC 100/50 BID and FSC 250/50
QD resulted in similar improvements from baseline (increase
of 38.4 and 40.2 L/min, respectively) whereas FP 250 QD
produced smaller changes (increase of 13.1 L/min, Figure 3).Safety
Overall, each of the treatments was well tolerated in this
12-week study. AEs were generally similar across groups
with 52–61% of subjects reporting any AE (Table 4). The
incidence of events considered potentially drug related by
the investigator ranged from 8% to 9% in each of the
active treatment groups and 4% in the placebo group
(Table 4). The most commonly reported drug-related AEs
(41 patient in any treatment group) were pharyngolaryngeal
pain and headache. A total of 11 serious adverse events
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Table 3 Efﬁcacy measures: treatment differences.
Treatment differences
FSC 250/50mcg QD vs.
FP 250mcg QD
FP 250mcg QD
vs. PLA
FSC 250/50mcg QD vs.
FSC 100/50mcg BID
% Predicted PM PEF (weeks 1–12)
Treatment difference (SE) 2.8 (0.83)a 2.3 (0.82)b 1.8 (0.83)b
95% Conﬁdence interval 1.2, 4.4 0.7, 3.9 3.4, 0.1
PM PEF (weeks 1–12)
Treatment difference (SE) 10.9 (3.88)b 12.2 (3.87)b 9.9 (3.89)b
95% Conﬁdence interval 3.3, 18.5 4.6, 19.8 17.6, 2.3
AM PEF (weeks 1–12)
Treatment difference (SE) 18.1 (4.08)a 21.0 (4.06)a 5.4 (4.08)
95% Conﬁdence interval 10.1, 26.1 13.0, 29.0 13.4, 2.6
AM FEV1 (endpoint)
Treatment difference (SE) 0.1 (0.04)b 0.2 (0.04)a 0.0 (0.04)
95% Conﬁdence interval 0.0, 0.2 0.1, 0.3 0.1, 0.1
24-h symptom score (endpoint)
Treatment difference (SE) 0.2 (0.13) 0.4 (0.13) 0.1 (0.13)
95% Conﬁdence interval 0.5, 0.0 0.7, 0.2 0.2, 0.3
2-h post-dose PM PEF
Treatment difference (SE) 27.0 (5.38)a 0.1 (5.47) 1.8 (5.04)
95% Conﬁdence interval 16.5, 37.6 10.8, 10.7 8.1, 11.7
24-h albuterol use (endpoint)
p value 0.041 o0.001 0.061
FSC, ﬂuticasone propionate/salmeterol; FP, ﬂuticasone propionate; PLA, placebo.
Comparison of treatment groups based on adjusted mean changes using ANCOVA.
Comparison based on non-parametric ANCOVA.
app0.001.
bpp0.033.
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Figure 2 Mean change from baseline in % predicted PM PEF.
E.M. Kerwin et al.500(SAEs), in eight patients, were reported. In the placebo
group, three patients had SAEs: appendicitis (two patients)
and asthma exacerbation. In the FSC 250/50 QD group, four
patients had SAEs: 4th degree glioblastoma (one patient),right ﬂank pain and renal calculi (one patient), acute
cholecystitis and cholelithiasis (one patient), atrial ﬁbrilla-
tion and supraventricular tachycardia (one patient). In the
FSC 100/50 BID group, one SAE of urinary tract infection was
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Table 4 Adverse events incidence X3% during treatment.
FSC 250/50mcg
QD n (%)
FP 250mcg
QD n (%)
FSC 100/50mcg
BID n (%)
PLA n (%)
Any AE 126 (60) 112 (53) 128 (61) 110 (52)
Headache 26 (12) 28 (13) 28 (13) 24 (11)
Nasopharyngitis 20 (10) 27 (13) 23 (11) 19 (9)
Upper respiratory tract infection, NOS 12 (6) 6 (3) 11 (5) 8 (4)
Pharyngolaryngeal pain 14 (7) 11 (5) 21 (10) 12 (6)
Sinusitis NOS 7 (3) 8 (4) 11 (5) 11 (5)
Back pain 6 (3) 8 (4) 8 (4) 5 (2)
Myalgia 4 (2) 7 (3) 5 (2) 3 (1)
Nasal congestion 3 (1) 6 (3) 5 (2) 2 (o1)
Dyspepsia 3 (1) 4 (2) 8 (4) 2 (o1)
Diarrhea 2 (o1) 1 (o1) 4 (2) 7 (3)
Nausea 6 (3) 3 (1) 4 (2) 2 (o1)
Inﬂuenza 6 (3) 4 (2) 1 (o1) 1 (o1)
Treatment related adverse events occurring in 41 patient in any treatment group
Any treatment related AE 19 (9) 16 (8) 17 (8) 8 (4)
Pharyngolaryngeal pain 4 (2) 3 (1) 5 (2) 3 (1)
Headache 4 (2) 5 (2) 2 (o1) 1 (o1)
Throat irritation 0 1 (o1) 3 (1) 0
Oral candidiasis 2 (o1) 1 (o1) 1 (o1) 0
Nausea 0 2 (o1) 2 (o1) 0
Hoarseness 1 (o1) 0 2 (o1) 0
Tremor 1 (o1) 0 2 (o1) 0
Dyspepsia 1 (o1) 3 (1) 0 0
Diarrhea 0 0 2 (o1) 0
Dry mouth 0 0 2 (o1) 0
FSC, ﬂuticasone propionate/salmeterol; FP, ﬂuticasone propionate; PLA, placebo.
NOS, not otherwise speciﬁed.
Use of ﬂuticasone propionate/salmeterol once daily 501reported. None of the SAEs reported were considered by the
investigator to be related to the study drug. The one asthma-
related SAE (asthma exacerbation) reported was in a patient
receiving placebo.Thirty-one patients were withdrawn due to worsening of
asthma, which was deﬁned as either a patient not meeting
one or more pre-deﬁned stability criteria or the occurrence
of an asthma exacerbation. Four patients in each FSC group
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17 patients in the placebo group (8%) were withdrawn of
whom 18 were classiﬁed as an asthma exacerbation (two
patients in each of the active treatment groups and 12
patients in the placebo group).
A total of 570 patients (X132 patients in each treatment
group) were included in the analysis of urinary cortisol
excretion. After 12 weeks of treatment the incidence of a
urinary cortisol excretion below the lower limit of normal
ranged from 0 too1% in any group. Two subjects, one in the
FSC 250/50 QD group and one in the FP 250 QD group, had a
urine cortisol excretion result below the lower limit of
normal. A histogram illustrating the distribution of the
change from baseline urinary cortisol excretion data is
presented in Figure 4.Discussion
The twice daily administration of an ICS has been shown to
effectively control asthma in patients with persistent
asthma. However, adherence to twice daily regimens of
asthma medications is low and complex dosing regimens may
be a contributing factor.20–22 The combination of an ICS and
LABA in one inhaler provides greater asthma control
compared with an ICS alone. A pooled analysis showed that
asthma outcomes are improved to a greater extent when FP
and salmeterol are administered in a single inhaler
compared with separate inhalers.23 In addition, two retro-
spective, observational studies found that the reﬁll rate for
patients taking FP plus salmeterol in one inhaler had a
greater reﬁll rate than those taking each in separate
inhalers or FP alone.24,25 Since a once daily dosing regimen
may lead to improved adherence and outcomes we
investigated the role of FSC once daily in a single inhaler.
Previous studies have evaluated the once daily adminis-
tration of FP in combination with salmeterol. In a cross-overstudy in adolescent/adult patients, Masoli et al.26 demon-
strated that a single dose of FSC 100/50mcg in the evening
resulted in a duration of bronchodilation of at least 24 h with
a linear decline in lung function contrasted with the biphasic
pattern of placebo or salmeterol alone. In another single-
dose, cross-over study in children Aldington et al.27 showed
that FSC 100/50mcg resulted in bronchodilation of at least
20 h when administered in the evening. In two studies
evaluating the combination of budesonide/formoterol once
daily in the evening compared with twice daily administra-
tion at the same total daily dose, the once daily regimen was
shown to be similar to the twice daily regimen in improving
asthma control.28,29
The patients in the current study, using only short-acting
beta2-agonists, demonstrated uncontrolled asthma upon study
entry with an FEV1 73–75% of predicted normal and corre-
sponding baseline asthma symptoms and rescue albuterol use.
All treatments were effective compared with placebo and the
two FSC treatments demonstrated the greatest improvements
in all efﬁcacy measures compared with ICS alone (FP 250 QD).
The FSC treatments were similar except that QD dosing did not
maintain improvements in lung function for 24h compared
with twice daily dosing. Improvements in lung function and the
patient reported outcomes of asthma symptoms and rescue
albuterol use were observed during the ﬁrst week of treatment
and sustained throughout the study for the FSC 250/50 QD and
FSC 100/50 BID patients. These ﬁndings suggest that a
subgroup of patients may beneﬁt with the once-a-day
approach, but future work is warranted for identifying the
speciﬁc phenotypic characteristics on this type of patients.
Clinical differences in asthma presentation have been recog-
nized and led to its description as a heterogeneous disorder. A
better understanding of patient’s phenotypic proﬁle will aid in
tailoring the most appropriate therapeutic approach.
Recently, Peters et al.30 reported that patients with mild
persistent asthma who were well controlled on a low dose
ICS (FP 100mcg BID) could be stepped down to a once daily
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BID, or montelukast (5 or 10mg) QD at night, or FSC 100/50mcg
QD at night. The number of subjects who had treatment
failure was similar for FP 100mcg BID and FSC 100/50mcg
QD groups (failure rate 20.2% and 20.4%, respectively)
compared with 30.3% for montelukast suggesting that
patients in this study who were well controlled on a
twice daily ICS could be stepped down to a once daily
treatment in the evening of FSC 100/50mcg. The current
study showed that, regardless of asthma severity, some
patients could be controlled on a once daily treatment in
the evening (FSC 250/50 QD). For these patients these
results could help by improving compliance and simplifying
asthma management. However, FSC 100/50mcg BID pro-
duced greater beneﬁts compared with a higher dose once
daily when lung function at the end of the therapeutic
dosing interval was compared. Whereas in Peters et al.,30
patients were stepped down after achieving control on an
ICS, in the current study patients needed to achieve control
from an unstable baseline.
Current guidelines recommend a stepwise approach to
pharmacologic therapy to gain and maintain control of
asthma in both the impairment and risk domains. However,
the type, amount, and scheduling of medication is dictated
by asthma severity for initiating therapy and the level of
asthma control for adjusting therapy. A step-down therapy
approach is essential to identify the minimum medication
necessary to maintain control.1
All study treatments were well tolerated. Drug-related AE
rates were low and consistent with known pharmacological
effects. Importantly, this study included 570 patients
in the 24-h urine cortisol excretion analysis. This large
sample showed that urine cortisol excretion for all active
treatment groups was generally similar to placebo demon-
strating the safety of these products with respect to HPA axis
activity.
In conclusion, this study conﬁrmed that FSC administered
either once daily in the evening (FSC 250/50 QD) or twice
daily (FSC 100/50 BID) achieves asthma control quickly and
more effectively than a once daily in the evening regimen of
FP 250 QD. For outcomes that measured the effect of
treatment on lung function after 24 h (evening [PM] PEF)
twice daily FSC compared with once daily FSC was more
effective, likely the result of the inherent bronchodilatory
properties of salmeterol. Nonetheless, the study suggests
that once daily FSC 250/50 may be an effective treatment
option for some patients.
Current asthma guidelines suggest an effective asthma
management plan should achieve asthma control resulting
in a productive normal life style not altered by asthma
symptoms. In addition, asthma treatment should be tar-
geted to protect or alter the airway from remodeling
and subsequent ﬁxed obstructive lung disease. ICS are
the only therapy available today that effectively treat
airway inﬂammation.1,2 Thus, strategies to reduce inﬂam-
mation and bronchoconstriction and subsequently improve
asthma control and enhance drug adherence to inhaled
therapy such as once-a-day dosing are of critical value.
However, the goal of convenient once-a-day dosing should
not supersede the goal of asthma control for patients
who require twice-a-day dosing to achieve optimal asthma
control.The need remains for the development of combination
ICS plus LABA asthma therapies that have a pharmacological
24-h duration for all patients.
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